Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system

International Journal of Cancer

Volumn 104, Issue 5, 2003, Pages 550-558

  Sabino, Mary Ann C ^a   Luger, Nancy M ^a   Mach, David B ^a   Rogers, Scott D ^a,b   Schwei, Matthew J ^a,b   Mantyh, Patrick W ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

^c 18 208 Moos Towers ^*  (United States)

Author keywords

Heterogeneity; Metastasis; Nociception; Osteo lysis; Sensitization; Tumor

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE DESTRUCTION; CANCER PAIN; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEMUR; MALE; MELANOMA; METASTASIS; NEUROCHEMISTRY; NOCICEPTION; NONHUMAN; OSTEOLYSIS; PRESSURE; PRIORITY JOURNAL; SARCOMA; SENSITIZATION; SPINAL CORD; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; CENTRAL NERVOUS SYSTEM; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM; TUMOR CELLS, CULTURED;

EID: 0037401028     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10999     Document Type: Article

References (82)

1. Ferlay J, Bray F, PP, DM, P. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0, IARC, WHO, Lyon: IARC, 2001.
2. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998;24:425-32.
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
4. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-700.
5. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247-57.
6. de Wit R, van Dam F, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Huijer Abu-Saad H. The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 2001;91:339-49.
7. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-6.
8. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
10. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life [see comments]. J Pain Symptom Manage 1990;5:83-93.
11. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
12. Weber M, Huber C. Documentation of severe pain, opioid doses and opioid-related side effects in outpatients with cancer: a retrospective study. J Pain Symptom Manage 1999;17:49-54.
13. Koshy RC, Grossman SA. Treatment of bone pain. In: Body JJ, ed. Tumor bone diseases and osteoporosis in cancer patients. New York: Marcel Dekker, 2000.
14. Ripamonti C, Fulfaro F. Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. Q J Nucl Med 2001;45:65-77.
15. Thurlimann B, de Stoutz ND. Causes and treatment of bone pain of malignant origin [see comments]. Drugs 1996;51:383-98.
16. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-97.
17. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
18. Luger NM, Honore P, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47.
19. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 1996;14:2-6.
20. Clohisy DR, Ramnaraine ML. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 1998;16:660-6.
21. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988;48:6876-81.
22. Sanchez-Sweatman OH, Lee J, Orr FW, Singh G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 1997;33:918-25.
23. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
24. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi MY, Lacey DL, Dunstan CR. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-7.
25. McBride WH. Phenotype and functions of intratumoral macrophages. Biochim Biophys Acta 1986;865:27-41.
26. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987;328:632-4.
27. Munglani R, Fleming BG, Hunt SP. Remembrance of times past: the significance of c-fos in pain [editorial: comment] [see comments]. Br J Anaes 1996;76:1-4.
28. Mantyh PW, Allen CJ, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum Al, Vigna SR, Maggio JE. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 1995;92:2622-6.
29. Honore P, Menning PM, Rogers SD, Nichols ML, Basbaum AI, Besson J-M, Mantyh PW. Spinal substance P receptor expression and internalization in acute, short-term and long-term inflammatory pain states. J Neurosci 1999;19:7670-8.
30. Abbadie C, Trafton J, Liu H, Mantyh PW, Basbaum AI. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci 1997;17:8049-60.
31. Molander C, Xu Q, Grant G. The cytoarchitectonic organization of the spinal cord in the rat: 1. The lower thoracic and lumbosacral cord. J Comp Neurol 1984;230:133-41.
32. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98.
33. Doyle CA, Hunt SP. Substance Preceptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat. Neuroscience 1999;89:17-28.
34. Hunt SP, Mantyh PW. The molecular dynamics of pain control [Review]. Nat Rev Neurosci 2001;2:83-91.
35. Vanderah TW, Laughlin T, Lashbrook JM, Nichols ML, Wilcox GL, Ossipov MH, Malan TP Jr, Porreca F. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 1996;68:275-81.
36. Vanderah TW, Ossipov MH, Lai J, Malan TP, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin [Review]. Pain 2001;92:5-9.
37. Laughlin TM, Vanderah TW, Lashbrook J, Nichols ML, Ossipov M, Porreca F, Wilcox GL. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997;72:253-60.
38. Kajander KC, Sahara Y, Iadarola MJ, Bennett GJ. Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 1990;11:719-28.
39. Noguchi K, Kowalski K, Traub R, Solodkin A, Iadarola MJ. Ruda MA. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord' neurons. Brain Res Mol Brain Res 1991;10:227-33.
40. Iadarola MJ, Douglass J, Civelli O, Naranjo JR. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization. Brain Res 1988;455:205-12.
41. MacArthur L, Ren K, Pfaffenroth E, Franklin E, Ruda MA. Descending modulation of opioid-containing nociceptive neurons in rats with peripheral inflammation and hyperalgesia. Neuroscience 1999;88:499-506.
42. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992;15:96-103.
43. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002;2:201-9.
44. Basbaum AI. Immediate-early genes and pain: What's all the "Fos" about? APS J 1994;3:49-52.
45. Jasmin L, Gogas KR, Ahlgren SC, Levine JD, Basbaum AI. Walking evokes a distinctive pattern of Fos-like immunoreactivity in the caudal brainstem and spinal cord of the rat. Neuroscience 1994;58:275-86.
46. Abbadie C, Taylor BK, Peterson MA, Basbaum AI. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain 1997;69:101-10.
47. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE, et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 1995;268:1629-32.
48. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li J, Lappi DA, Simone DA, Mantyh PW. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 1999;286:1558-61.
49. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain 1999;82:263-74.
50. Cain DM, Wacnik PW, Turner M, Wendelschafer-Crabb G, Kennedy WR, Wilcox GL, Simone DA. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 2001;21:9367-76.
51. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon G, Winter J, Green J, et al. A rat model of bone cancer pain. Pain 2002;96:129-40.
52. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL. Functional interactions between tumor and peripheral nerve: morphology, algogen identification and behavioral characterization of a new murine model of cancer pain. J Neurosci 2001;21:9355-66.
53. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80:1674-9.
54. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978;276:726-8.
55. Eilon G, Mundy GR. Association of increased cyclic adenosine 3′: 5′-monophosphate content in cultured human breast cancer cells and release of hydrolytic enzymes and bone-resorbing activity. Cancer Res 1983;43:5792-4.
56. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998;18:297-305.
57. Hukkanen M, Konttinen YT, Rees RG, Gibson SJ, Santavirta S, Polak JM. Innervation of bone from healthy and arthritic rats by substance P and calcitonin gene related peptide containing sensory fibers. J Rheumatol 1992;19:1252-9.
58. Kruger L, Silverman JD, Mantyh PW, Stemini C, Brecha NC. Peripheral patterns of calcitonin-gene-related peptide general somatic sensory innervation: cutaneous and deep terminations. J Comp Neurol 1989;280:291-302.
59. Hill EL, Elde R. Distribution of CGRP-, VIP-, DbH-, SP- and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res 1991;264:469-80.
60. Hukkanen M, Konttinen YT, Rees RG. Santavirta S, Terenghi G, Polak JM. Distribution of nerve endings and sensory neuropeptides in rat meniscus and bone. Int J Tissue React 1992;14:1-10.
61. Tabarowski Z, Gibson-Berry K, Felten SY. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem 1996;98:453-7.
62. Bjurholm A, Kreicbergs A, Terenius L, Goldstein M, Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Auton Nerv Syst 1988;25:119-25.
63. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P-and CGRP-immunoreactive nerves in bone. Peptides 1988;9:165-71.
64. Haegerstam GA. Pathophysiology of bone pain: a review. Acta Orthop Scand 2001;72:308-17.
65. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW. Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience 2002;113:155-66.
66. Rubens RD. Clinical aspect of bone metastases. In: Body J-J, ed. Tumor bone disease and osteoporosis in cancer patients. New York: Marcel Dekker. 2000. 85-96.
67. Zhu ZW, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, Buchler MW. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999;17:2419-28.
68. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-65.
69. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
70. Koltzenburg M, Bennett DL, Shelton DL, McMahon SB. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur J Neurosci 1999;11:1698-704.
71. McMahon SB, Bennett DL, Priestley JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995;1:774-80.
72. Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000;20:6289-93.
73. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med 2001;2:24-7.
74. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia [Review]. Crit Rev Clin Lab Sci 2000;37:431-502.
75. Nicol GD, Klingberg DK, Vasko MR. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons. J Neurosci 1992;12:1917-27.
76. Sauer SK, Bove GM, Averbeck B, Reeh PW. Rat peripheral nerve components release calcitonin gene-related peptide and prostaglandin E-2 in response to noxious stimuli: evidence that nervi nervorum are nociceptors. Neuroscience 1999;92:319-25.
77. Ogino M, Hisatomi H, Murata M, Hanazono M. Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Jpn J Cancer Res 1999;90:758-64.
78. Cahlin C, Gelin J, Delbro D, Lonnroth C, Doi C, Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 2000;60:1742-9.
79. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K. Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
80. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
81. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St. Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-6.
82. Pomonis JD, Rogers SD, Peters CM, Ghilardhi JR, Mantyh PW. Expression and localization of endothelin receptors: implication for the involvement of peripheral glia in nociception. J Neurosci 2001;21:999-1006.